StockMarketWire.com - Tiziana Life Sciences, which is focused on the development of therapeutics for inflammation and oncology indications, said it had recorded positive safety data from a clinical trial.

An independent data monitoring committee reviewed safety data from patients as of February 26.

It concluded that the administration of milciclib to patients with advanced hepatocellular carcinoma was not associated with unexpected signs or signals of toxicity.

Additionally, a number of patients were continuing with treatment under compassionate use.

Topline data was expected to be available by the end of the third quarter of 2019.

So far, no drug-related deaths had been recorded.

'Demonstration of safety and clinical activity is important milestone to move forward with strategic options for further clinical development of milciclib either as a single agent or in combination with one of the FDA approved drugs for treatment of HCC patients,' said chief executive Kunwar Shailubhai.



Story provided by StockMarketWire.com